Sloan Sheldon's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Jun 3, 2026
- Accession no.
- 0001636282-26-000078
- Filed
- Jun 3, 2026
- Trade date
- Jun 3, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $625.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sloan SheldonCIK 0002038798 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Common Stock | MOption exerciseAcquired | +8,333 | $27.46 | +$228,824.18 | 8,333 | Direct | |
| Jun 3, 2026 | Common Stock | SSaleDisposed | −8,333 | $75.00 | −$624,975 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Common Stock | MOption exerciseDisposed | −8,333 | $0.00 | $0 | 313,334 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.